Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

plaintiffappealmotionsummary judgmentpatenttrademarkmotion for summary judgmentdeclaratory judgment
plaintiffappealmotionsummary judgmentpatenttrademarkmotion for summary judgmentdeclaratory judgment

Related Cases

Jackson v. Magnolia Brokerage Co., 742 F.2d 1305
View Case »
Island Federal Credit Union v. Smith, 60 A.D.3d 730, 875 N.Y.S.2d 198, 2009 N.Y. Slip Op. 01776
View Case »
Smith v. Deneve, 285 S.W.3d 904
View Case »
Tasini v. AOL, Inc., 851 F.Supp.2d 734, 40 Media L. Rep. 1641
View Case »
Com. of Puerto Rico v. SS Zoe Colocotroni, 61 F.R.D. 653, 18 Fed.R.Serv.2d 322
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Association for Molecular Pathology v. U.S. Patent and Trademark Office, 689 F.3d 1303, 103 U.S.P.Q.2d 1681

Facts

Medical organizations, researchers, genetic counselors, and patients brought an action against Myriad Genetics and the Patent and Trademark Office (PTO) to challenge the validity of patents for isolated DNA sequences linked to breast and ovarian cancers. The plaintiffs argued that the patents were invalid under 35 U.S.C. § 101, claiming that isolated DNA sequences are products of nature and thus not patentable. The district court granted the PTO's motion and partially granted the plaintiffs' motion for summary judgment, leading to an appeal by Myriad.

Medical organizations, researchers, genetic counselors, and patients brought an action against Myriad Genetics and the Patent and Trademark Office (PTO) to challenge the validity of patents for isolated DNA sequences linked to breast and ovarian cancers. The plaintiffs argued that the patents were invalid under 35 U.S.C. § 101, claiming that isolated DNA sequences are products of nature and thus not patentable. The district court granted the PTO's motion and partially granted the plaintiffs' motion for summary judgment, leading to an appeal by Myriad.

Issue

The main legal issues were whether the plaintiffs had standing to challenge Myriad's patents and whether the patents for isolated DNA sequences and associated diagnostic methods were drawn to patentable subject matter under 35 U.S.C. § 101.

The main legal issues were whether the plaintiffs had standing to challenge Myriad's patents and whether the patents for isolated DNA sequences and associated diagnostic methods were drawn to patentable subject matter under 35 U.S.C. § 101.

Rule

The court applied the legal principles surrounding patent eligibility under 35 U.S.C. § 101, particularly the exceptions for products of nature and abstract ideas, as well as the standing requirements under the Declaratory Judgment Act.

The court applied the legal principles surrounding patent eligibility under 35 U.S.C. § 101, particularly the exceptions for products of nature and abstract ideas, as well as the standing requirements under the Declaratory Judgment Act.

Analysis

The court found that at least one plaintiff had standing to challenge the patents, as they had expressed a clear intent to resume clinical testing if the patents were invalidated. The court then analyzed the composition claims, determining that isolated DNA molecules were not products of nature because they represented nonnaturally occurring compositions. However, the court held that method claims for analyzing DNA sequences were patent ineligible as they involved only abstract mental processes without transformative steps.

The court found that at least one plaintiff had standing to challenge the patents, as they had expressed a clear intent to resume clinical testing if the patents were invalidated. The court then analyzed the composition claims, determining that isolated DNA molecules were not products of nature because they represented nonnaturally occurring compositions. However, the court held that method claims for analyzing DNA sequences were patent ineligible as they involved only abstract mental processes without transformative steps.

Conclusion

The court affirmed the district court's ruling that Myriad's method claims were not patentable but reversed the ruling regarding the composition claims, holding that isolated DNA sequences were patentable subject matter. The case was remanded for further proceedings consistent with the Supreme Court's decision.

The court affirmed the district court's ruling that Myriad's method claims were not patentable but reversed the ruling regarding the composition claims, holding that isolated DNA sequences were patentable subject matter. The case was remanded for further proceedings consistent with the Supreme Court's decision.

Who won?

The prevailing party was the plaintiffs, as the court affirmed the invalidation of Myriad's method claims and recognized the standing of at least one plaintiff to challenge the patents.

The prevailing party was the plaintiffs, as the court affirmed the invalidation of Myriad's method claims and recognized the standing of at least one plaintiff to challenge the patents.

You must be